This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sharara, A.I., Hunt, C.M., et al., 1996, Hepatitis C. Ann Intern Med 125:658–68.
Koziel, M.J., 1996, Immunology of viral hepatitis. Am J Med 100:98–109.
Kiyasu, P.K. and Caldwell, S.H., 1993, Diagnosis and treatment of the major hepatotropic viruses. Am J Med Sci 306: 248–61.
Iwarson, S., Norkraus, G. et al., 1995, Hepatitis C: natural history of a unique infection. Clin Infect Dis 20: 1361–70.
Alter, M., 1997, Epidemiology of hepatitis C. Hepatology 26:(3 Suppl 1): 625–655.
Davis, G.L., 2000, Current therapy for chronic hepatitis C. Gastroenterol 118(Suppl 1): S104–S114.
Lawrence, S.P., 2000, Advances in the treatment of hepatitis C. In Advances in Internal Medicine. Mosby, St. Louis.
Hoofnagle, J.H. and di Bisceglie, A.M., 1997, The treatment of chronic viral hepatitis. N Engl J Med 336: 347–56.
McHutchinson, J.G., Gordon, S.C., et. al., 1998, Interferon alfa-2b or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485–92.
Wills, R.J., 1990, Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390–399.
Bocci, V., Pacini, A. et. al., 1981, Renal filtration, absorption and catabolism of human alpha interferon. J Interferon Res 1: 347–52.
Zeuzem, S., Herrmann, E. et. al., 2001, Viral kinetics with chronic hepatitis C patients treated with standard or peginterferon alfa-2a. Gastroenterol 120: 1438–1447.
Lam, N.P. Neumann, A.U. et. al., 1997, Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26: 226–31.
Zhi, J., Teller, S.B. et al., 1995, Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2b given by subcutaneous injection in healthy male volunteers. J Clin Pharmacol 35: 281–4.
Harris, J.M., Martin, N.E., et. al., 2001, Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539–51.
Yamaoka, T., Tabata, Y., et. al., 1994, Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm Sci 83: 601–6.
Fung, W.-J., Porter, J.E., et. al., 1997, Strategies for the preparation and characterization of polyethylene glycol vinyl sulfone. Polymers Preprint: 565–66.
Nieforth, K.A., Nadeau, R., et. al., 1996, Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 59: 636–46.
Xu, Z.-X., Patel, I., et al., 1998, Single-dose safety, tolerability and pharmacokinetics of PEG-FIN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 28(Suppl): 702.
Bailon, P., Palleroni, A., et al., 2001, Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem 12: 195–202.
Bailon, P., Spence, C., et al., 1999, Pharmacokinetic properties of five polyethylene glycol conjugates of interferon alfa-2a. Antiviral Therapy 4(Suppl 4): 27.
Harris, N.J., Veronese, F.M., et al., 1999, Multiarmed, monofunctional, polymer for coupling to molecules and surfaces. US Patent & Trademark Office, USA.
Algranati, N.E., Sy, S., et. al., 1999, A branched methoxy 40 kDa, polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of PEG-IFN alfa-2a and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 40: 190.
Modi, M.W., Fried, M.W., et. al., 2000, The pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a (PEGASYS) in chronic hepatitis patients after multiple dosing. Hepatology 32 (4 Pt 2 of 2): 394A.
Zeuzem, S., Feinman, S.V., et al., 2000, Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666–72.
Heathcote, E.J., Shiftman, M.J., et. al., 2000, Peginterferon alfa-2a in patieints with chronic hepatitis C and cirrhosis. N Engl J Med 345: 1673–80.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Modi, M.W., Lamb, M.W., Shiomi, M. (2004). Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C. In: Maeda, H., Kabanov, A., Kataoka, K., Okano, T. (eds) Polymer Drugs in the Clinical Stage. Advances in Experimental Medicine and Biology, vol 519. Springer, Boston, MA. https://doi.org/10.1007/0-306-47932-X_4
Download citation
DOI: https://doi.org/10.1007/0-306-47932-X_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-47471-2
Online ISBN: 978-0-306-47932-8
eBook Packages: Springer Book Archive